A Novel Neutrophil-Based Biomarker to Monitor Disease Activity and Predict Response to Infliximab Therapy in Patients With Ulcerative Colitis.

Zhou, Zhou; Zhang, Yinghui; Pan, Yan; Yang, Xue; Li, Liangping; Gao, Caiping; He, Chong

Zhou, Zhou; Zhang, Yinghui; Pan, Yan; Yang, Xue; Li, Liangping; Gao, Caiping; He, Chong.

Afiliação

Zhou Z; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Zhang Y; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Pan Y; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Yang X; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Li L; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
Gao C; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
He C; Department of Gastroenterology, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.

Front Med (Lausanne) ; 9: 872831, 2022.

Article em En | MEDLINE | ID: mdl-35572985

Palavras-chave

albumin; biomarker; inflammatory bowel disease; infliximab; neutrophil; neutrophil-to-albumin ratio; ulcerative colitis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google